3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Interventions
Cisplatin
24
pembrolizumab
23
Magnetic Resonance Spectroscopy
19
Specimen Handling
16
Radiotherapy, Intensity-Modulated
12
Carboplatin
12
Cetuximab
11
1,2-diaminocyclohexaneplatinum II citrate
10
Platinum
9
Paclitaxel
9
Radiotherapy
6
Radiation
6
Fluorouracil
6
Biopsy
5
Taxes
4
Nivolumab
4
Docetaxel
4
(225)Ac-DOTA-c(RGDyK)
4
X-Rays
3
Pemetrexed
3
Fluorodeoxyglucose F18
3
reolysin
2
pralsetinib
2
ipatasertib
2
cemiplimab
2
atezolizumab
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma
×
pralsetinib
×
Head & Neck
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA